Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis

Nadja Sparding 1,2, Federica Genovese 1, Daniel Guldager Kring Rasmussen 1, Morten Asser Karsdal 1, Michaela Neprasova 3, Dita Maixnerova 3, Veronika Satrapova 3, Doubavka Frausova 3, Mads Hornum 4,5, Lenka Bartonova 6, Eva Honsova 6, Marek Kollar 6, Helena Koprivova 7, Zdenka Hruskova 3 and Vladimir Tesar 3

1Nordic Bioscience, Herlev, Denmark, 2Faculty of Health and Medical Science, Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 3Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, 4Department of Nephrology, Rigshospitalet, Copenhagen, Denmark, 5Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 6Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic and 7Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Correspondence to: Nadja Sparding; E-mail: nas@nordicbio.com

GRAPHICAL ABSTRACT
ABSTRACT

Background. Renal fibrosis is the hallmark of chronic kidney disease (CKD) and is characterized by an imbalanced extracellular matrix remodelling. Endotrophin (ETP) is a signalling molecule released from collagen type VI (COL VI). ETP can be measured by the PRO-C6 assay, which quantifies the levels of COL VI formation. ETP levels were previously associated with mortality and disease progression in different populations of CKD patients; however, the level of ETP has not been directly linked to the degree of interstitial fibrosis in patients with immunoglobulin A nephropathy (IgAN) and patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Methods. We examined a cohort of 49 IgAN and 47 AAV patients. A validation cohort of 85 IgAN patients was included. ETP was measured in serum (S-ETP) and urine (U-ETP/Cr) samples, taken on the same day before renal biopsy was performed, using the enzyme-linked immunosorbent assay PRO-C6. The biopsies were evaluated for interstitial fibrosis and tubular atrophy according to the Banff and MEST-C scores.

Results. S-ETP and U-ETP/Cr levels correlated with kidney function, increased CKD severity, correlated with the extent of interstitial fibrosis and gradually increased with increasing degree of interstitial fibrosis and tubular atrophy. ETP outperformed the known fibrosis marker Dickkopf-3 for discrimination of patients with advanced fibrosis.

Conclusions. We demonstrated that high levels of circulating and excreted ETP are not only indicative of lower kidney function, but also reflect the burden of fibrosis in the kidneys.

Keywords: ANCA-associated vasculitis, biomarkers, chronic kidney disease, IgA nephropathy, interstitial fibrosis

INTRODUCTION

Immunoglobulin A nephropathy (IgAN) is one of the most common primary diagnoses leading to glomerulonephritis worldwide [1], representing ~20% of all biopsy findings [2]. It is caused by an increased level of poorly O-galactosylated IgA1 glycoforms resulting in the deposition of IgA1-containing immune complexes in the glomerular mesangium causing glomerular injury [3, 4]. IgAN is a slowly progressive disease [5] characterized by onset at young age with apparent benign course during short-term follow-up; however, 20–40% of patients progress to end-stage kidney disease (ESKD) within 20 years [4].

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) occurs in only 5% of renal biopsies [2] and is a group of heterogeneous diseases associated with ANCAs directed against proteinase 3 (PR3) or myeloperoxidase (MPO) in 95% of the patients [6, 7]. This group of diseases is usually characterized by severe and partly reversible renal injury at presentation with putative progression to ESKD due to non-
immunologic mechanisms and/or renal relapses [8–10]. Renal involvement is found in up to 90% of the patients with AAV [11]. In contrast to IgAN, AAV is a rare disease with a much later median age at disease onset. AAV is more progressive than IgAN and up to 20–40% of AAV patients develop ESKD within 5 years [4, 12].

Renal fibrosis is the hallmark of chronic kidney disease (CKD) [13, 14] and fibrosis is caused by an imbalance in the turnover of extracellular matrix (ECM) components such as collagens. Seminal studies have shown that collagens are not merely structural entities but can release fragments with paracrine and endocrine properties, termed matrikines [15, 16]. Collagen type VI (COL VI) is an important structural collagen found in the interface between the interstitial matrix and the basement membrane in the kidney, where it is produced by fibroblasts [17]. COL VI is expressed at low levels in healthy adult kidney [18], and is markedly upregulated in patients with renal fibrosis [19, 20]. The C-terminal of the α3 chain of COL VI is cleaved off the mature molecule upon secretion from the producing cell and can therefore be used as a biomarker of COL VI formation [21, 22]. Interestingly, the released fragment, called endotrophin (ETP), has important biological effects such as attracting macrophages, increasing transforming growth factor β expression, promoting epithelial–mesenchymal transition, adipose tissue fibrosis and metabolic dysfunction [22, 23]. The PRO-C6 enzyme-linked immunosorbent assay (ELISA) detects levels of ETP. High levels of ETP in serum have previously been associated with an increased risk of mortality and disease progression in patients with CKD and diabetic kidney disease [19, 24, 25].

Dickkopf (DKK)-3 is a stress-induced tubular epithelial-derived glycoprotein, which has shown pro-fibrotic activity in kidney disease [26], and high levels in urine have been shown to be associated with higher risk of kidney function loss. Urinary DKK3 also improved the prediction of kidney function loss compared with that of estimated glomerular filtration rate (eGFR) or albuminuria alone [27].

In this study, we investigated for the first time whether levels of ETP in serum and urine samples collected on the day of renal biopsy correlated with the degree of histological fibrosis in patients with IgAN (in a discovery and a validation cohort) and in patients with AAV, and we compared the ability of ETP and DKK-3 to reflect kidney fibrosis.

MATERIALS AND METHODS

Study subjects

The examined study cohort consisted of patients with biopsy-proven IgAN (n = 49) and patients with AAV (n = 47) diagnosed at the General University Hospital in Prague, Czech Republic. All consecutive patients with AAV diagnosed between 2011 and 2016 and with IgAN diagnosed between 2011 and 2013, with a representative biopsy sample, available specimens in local biobank and who were willing to participate in this research study were included. A validation cohort of 85 patients with IgAN, consisting of patients with available urine and serum samples and representative biopsy diagnosed between 2012 and 2015, was added. Blood and urine samples were taken on the same day before renal biopsy was performed. Ten healthy volunteers were enrolled as controls, and blood and urine samples were collected in the same hospital following the same procedures.

Follow-up data were available for IgAN patients 1 year after diagnosis (n = 32) and during the follow-up patients received either steroids alone, steroids combined with other immunosuppressive drugs or renin–angiotensin system blockade only. The AAV patients all received corticosteroids plus cyclophosphamide at entry, and were treated with corticosteroids combined with other immunosuppressive drugs (mostly azathioprine) or (less commonly) corticosteroids only at 1 year (n = 45) and at 3 years (n = 31) follow-up.

The study was conducted in compliance with the declaration of Helsinki principles. Informed consent was obtained from the participants.

Data collection

Clinical and laboratory data were collected or measured in the laboratories of the General University Hospital, including sex, age, serum creatinine (sCr), proteinuria (PU), C-reactive protein (CRP), haemoglobin, ANCA levels and ANCA type (all routinely measured). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [28], and patients were stratified based on eGFR according to the CKD classification.

Renal biopsy

Ultrasound-guided renal biopsies were collected for diagnostic purposes. All biopsies were classified according to official international classifications, such as MEST-C and Berden’s in combination with Banff classification, while glomerular morphology and interstitial fibrosis with tubular atrophy were evaluated in both groups.

Evaluation of fibrosis. Inasmuch as Berden’s classification does not include evaluation of interstitial fibrosis, the Banff classification was used in both groups (IgAN and AAV) for direct comparison of interstitial fibrosis. T-score of MEST-C score was used in patients with IgAN as well. Quantitative criteria for T-score in IgAN were used: T0: ≤25%, T1: 26–50% and T2: >50% [29]. Similarly, the Banff criteria were as follows: interstitial fibrosis in cortical area: c0: in up to 5%, c1: in 6–25% (mild), c2: in 26–50% (moderate) and c3: in >50% (severe) [30]. All biopsies were also evaluated for the percentage level of fibrosis (continuous variable).

Evaluation of glomeruli. MEST-C score was used to describe and classify morphology in IgAN. The glomerular morphology in the biopsies from AAV patients was classified by Berden’s classification as either focal (≥50% of normal glomeruli), mixed (<50% of normal, <50% of crescentic and <50% of globally sclerotic glomeruli), crescentic (≥50% of glomeruli with cellular crescents) or sclerotic (≥50% of globally sclerotic glomeruli) [31].
Table 1. Baseline characteristics and baseline biopsy evaluation

| Variables                          | Healthy | IgAN discovery | AAV discovery | IgAN validation | n (IgAN discovery/AAV discovery/IgAN validation) |
|------------------------------------|---------|----------------|---------------|----------------|-----------------------------------------------|
| n                                  | 10      | 49             | 47            | 85             | (49/47/85)                                    |
| Women, %                           | 90      | 20             | 40            | 37             | (49/47/85)                                    |
| Age, years                         | 41 (39–42)* | 42 (33–56)    | 62 (55–69)** | 43 (32–54)** | (49/47/85)                                    |
| sCr, mg/dL                         | NA      | 1.6 (1.0–3.0)  | 3.6 (1.6–6.8)** | 1.7 (1.1–2.4)** | (49/47/85)                                    |
| eGFR, mL/min/1.73 m²               | NA      | 47 (20–95)     | 17 (8–42)     | 45 (26–74)** | (49/47/85)                                    |
| PU, g/day                          | NA      | 1.3 (0.8–3.6)  | 1.4 (0.6–2.0)** | 2.0 (1.1–2.4)** | (49/47/85)                                    |
| CRP, mg/L                          | NA      | 2.4 (1.0–4.4)  | 38.1 (5.4–104.8)** | NA             | (44/47/NA)                                    |
| Haemoglobin, g/L                   | NA      | NA             | NA            | 101 (91–111)   | (NA/47/NA)                                    |
| ANCA levels, IU/mL                 | NA      | NA             | 77 (32–100)   | NA             | (NA/45/NA)                                    |
| ANCA type, n (MPO/PR3)             | NA      | NA             | (23/21)*      | NA             | (NA/47/NA)                                    |
| CKD stages (1–5), %                | NA      | 29, 12, 29, 10, 20 | 4, 9, 21, 26, 40 | 14, 19, 33, 26, 8 | (49/47/85)                                    |
| Level of fibrosis, %               | NA      | 20 (10–30)     | 15 (14–30)** | 30 (15–45)** | (45/42/83)                                    |
| Sclerotic glomeruli, %             | NA      | NA             | 21 (8–43)     | NA             | (NA/44/NA)                                    |
| Lung fibrosis (yes/no), yes %      | NA      | NA             | 17            | NA             | (NA/47/NA)                                    |
| Banff score (ci0–ci3), %           | NA      | 17, 31, 31, 21 | 9, 56, 19, 16 | 8, 37, 41, 14 | (48/43/83)                                    |
| T-score (T0–T2), %                 | NA      | 52, 27, 21     | NA            | NA             | (48/NA/NA)                                    |
| AAV classification scheme          | NA      | NA             | 27, 24, 22, 27 | NA             | (NA/45/NA)                                    |

Continuous variables are expressed as median or % (IQR) and categorical variables as % or n. The significant differences of continuous variables between groups were analysed with the Kruskal–Wallis test. NA, not available.

*P < 0.001.

****P < 0.0001 versus the IgAN patient group.

ns, not significant.

*Three of the 47 AAV patients were both MPO and PR3 positive and were not included in one of the ANCA type groups.

**Assays**

Serum levels and urinary excretion of ETP (S-ETP and U-ETP) were measured using a competitive ELISA, PRO-C6, according to manufacturer’s instructions (Nordic Bioscience, Herlev, Denmark) [24, 32]. DKK-3 was measured in serum (S-DKK-3) and urine (U-DKK-3) with a Human DKK-3 ELISA Kit (Sigma Aldrich, St Louis, MO, USA) in the laboratories of the General University Hospital. Urine Cr levels were measured with the QuantiChrom™ Creatinine kit (BioAssay Systems) and U-ETP as well as U-DKK-3 levels were normalized for urine Cr (U-ETP/Cr and U-DKK-3/Cr). Serum and urine samples for ETP and DKK-3 measurements were not available for all 49 IgAN (S-ETP n = 49, U-ETP n = 47, S-DKK-3, n = 47; U-DKK-3, n = 39) and 47 AAV patients (S-ETP n = 47, U-ETP, n = 44; S-DKK-3, n = 45; U-DKK-3, n = 37), or for the 85 IgAN patients included in the validation cohort (S-ETP, n = 85; U-ETP, n = 61).

**Statistical analyses**

For non-parametric statistical analysis, untransformed data were used and log_{10}-transformed data were used for parametric statistical analysis. Spearman’s rank correlation coefficient was used to estimate the correlation between variables. Multiple linear regression analysis was used to analyse the association of variables with fibrosis levels. The statistical differences between groups were analysed with the Mann–Whitney or the Kruskal–Wallis test. Receiver operating characteristic (ROC) curve analysis was used to evaluate discriminatory power of biomarkers for fibrosis scores and AAV histologic classification scheme. Comparison of C-statistics was used to evaluate the superiority of the different biomarkers to discriminate patients with a biopsy scored as ci3 according to the Banff score from patients with a biopsy scored as ci0–ci2. ROC curve analysis was also used to determine the ability of baseline ETP to discriminate between AAV patients with a decrease in CKD stage from patients with no change or an increase in CKD stage from baseline to the 3-year follow-up. Statistical analyses were performed using GraphPad Prism version 7.04 and MedCalc version 14.8.1. P < 0.05 were considered significant.

**RESULTS**

**Baseline characteristics of the study cohort**

The discovery cohort of this study included 49 patients with IgAN and 47 patients with AAV. The demographic and clinical data as well as the distribution of the IgAN and AAV patients in fibrosis classes according to the Banff score, the T-score (IgAN only) and the glomerular morphology (AAV only) are summarized in Table 1. Ten healthy volunteers were included as well as a validation cohort of 85 patients with IgAN. The validation cohort was not significantly different from the IgAN patients in the discovery cohort (Table 1).

**Associations of ETP and DKK-3 with baseline clinical parameters**

Both S-ETP and U-ETP/Cr measured in IgAN and AAV patients correlated with sCr, PU and inversely correlated with eGFR (Table 2). S-ETP and U-ETP/Cr were highly correlated (r = 0.72, P < 0.001). In AAV patients, ETP levels correlated with CRP and inversely correlated with haemoglobin, whereas there was no correlation with ANCA levels (Table 2). S-ETP and U-ETP/Cr levels were significantly higher in patients with
In IgAN and AAV patients, both S-DKK-3 and U-DKK-3/Cr levels were increased in biopsies with the highest ci3 compared with ci0–ci2 (P < 0.05 and P < 0.001, respectively; Figure 1D). However, levels of S-DKK-3 were not significantly elevated in IgAN patients with kidney biopsy scored as T1 or T2 compared with T0 (T-score; Figure 1F). In addition, U-DKK-3/Cr (AUC = 0.755, P < 0.001; Table 3) but not S-DKK-3 (AUC = 0.605, P = 0.15; Table 3) was able to discriminate biopsies with advanced interstitial fibrosis (ci3).

### Comparison of biomarker association with fibrosis levels

Based on multiple regression analyses including S-ETP, U-ETP/Cr, S-DKK-3 and U-DKK-3/Cr (all log10-transformed), only S-ETP was independently associated with the level of fibrosis [Model 1; \( \log_{10}(S-ETP) \) \( r_{\text{partial}} = 0.47 \), P < 0.001; Table 4]. To assess whether the investigated biomarkers added to sCr, sCr was added to the previous model. Only S-ETP [\( \log_{10}(S-ETP) \) \( r_{\text{partial}} = 0.38 \), P < 0.01] and not sCr [\( \log_{10}(sCr) \) \( r_{\text{partial}} = 0.04 \), P = 0.72], was retained in the model and correlated significantly with the level of fibrosis (Model 2; Table 4).

We investigated the univariate association of all variables available with the extent of fibrosis in the combined IgAN and AAV discovery cohort (Table 2), sCr, PU, S-ETP, U-ETP/Cr, S-DKK-3 and U-DKK-3/Cr (all log10-transformed) had a significant univariate association with the extent of fibrosis. All these variables were included in a multiple regression analysis with sequential forward selection (Model 4). Only S-ETP was retained in the final model (Model 4; \( \log_{10} r_{\text{partial}} = 0.65 \), P < 0.0001; Table 4).

### Comparison of biomarker discrimination ability for advanced fibrosis

S-ETP and U-ETP/Cr had superior discriminatory power compared with S-DKK-3 and U-DKK-3/Cr, respectively
were not significantly different from sCr (AUC = 0.795, $P < 0.001$; comparison of ROC curves, $P = 0.90$ and $P = 0.39$) (Table 3).

**Validation of the association of ETP with fibrosis levels and its discrimination ability for advanced fibrosis**

The validation cohort of 85 patients with IgAN confirmed the association of S-ETP and U-ETP/Cr with the level of kidney fibrosis (Figure 3B and C, Table 2) and the discrimination ability for advanced fibrosis (Table 3). In a multiple regression analysis, both S-ETP ($\log_{10}(S\text{-ETP})$ $r_{\text{partial}} = 0.35$, $P < 0.01$; $\log_{10}(s\text{Cr})$ $r_{\text{partial}} = 0.32$, $P < 0.01$) and U-ETP/Cr [log10(U-ETP/Cr) $r_{\text{partial}} = 0.29$, $P = 0.03$; log10(sCr) $r_{\text{partial}} = 0.29$, $P = 0.02$] were independently associated with fibrosis levels when adjusting for sCr, whereas only S-ETP and not U-ETP/Cr was independently associated with fibrosis levels in the discovery cohort.
Morphology evaluation of AAV biopsies

In the AAV population, renal biopsies were classified according to the histologic classification scheme for glomerular damage as focal, mixed, crescentic or sclerotic [33] with the focal phenotype being associated to the best and the sclerotic phenotype being associated to the worst prognosis. The percentage of sclerotic glomeruli evaluated in the AAV biopsies correlated significantly with S-ETP, U-ETP/Cr and the level of fibrosis (Table 2). S-ETP levels were higher in AAV patients with biopsies classified as both crescentic and sclerotic compared with patients with biopsies classified as focal (P < 0.01 and P < 0.001, respectively; Figure 1G). U-ETP/Cr levels were significantly elevated in patients with the sclerotic phenotype (P < 0.01; Figure 1G). S-DKK-3 levels were significantly elevated in patients with the mixed compared with the focal phenotype (P < 0.001; Figure 1H). Based on ROC curve analysis, both S-ETP and U-ETP/Cr could discriminate patients with biopsies classified as focal from the other classifications [AUC for S-ETP = 0.816 (95% CI 0.672–0.915), P < 0.001; AUC for U-ETP/Cr = 0.758 (95% CI 0.602–0.877), P < 0.001].

ANCA types

There was no difference in S-ETP [median MPO: 23.36 (interquartile range (IQR) = 18.01–37.78] ng/mL, PR3: 25.52 (IQR = 18.73–49.27] ng/mL, P = 0.83] and U-ETP/Cr [median MPO: 16.24 (IQR = 5.98–54.49] ng/mg, PR3: 24.44 (IQR = 5.98–54.49) ng/mg, P = 0.83] levels between AAV patients with different ANCA types. The level of fibrosis was not significantly different in the AAV patients with different ANCA types (MPO versus PR3, P = 0.10).

Pulmonary fibrotic changes

We investigated whether the elevated ETP levels in the patients with AAV were influenced by pulmonary involvement with signs of fibrotic changes. Neither S-ETP nor U-ETP/Cr were influenced by pulmonary involvement [S-ETP median with pulmonary fibrotic changes: 24.70 (IQR = 21.69–34.17] ng/mL, without pulmonary fibrotic changes: 25.64 (IQR = 19.21–40.83] ng/mL, P = 0.79; U-ETP/Cr median with pulmonary fibrotic changes: 8.26 (IQR = 6.07–47.90] ng/mg, without pulmonary fibrotic changes median: 24.94 (IQR = 4.59–58.70] ng/mg, P = 0.78].

Change in kidney function from baseline to follow-up

A 1-year clinical follow-up was available for all IgAN and AAV patients. S-ETP and U-ETP/Cr baseline levels were not significantly different between patients that regressed, remained stable and progressed in CKD stage. Patients who experienced a decrease in CKD stage (regression) had significantly higher S-ETP levels patients regressed, 11 patients remained stable and 4 patients progressed in CKD stage. Patients who experienced a decrease in CKD stage (regression) had significantly higher S-ETP levels patients regressed, 11 patients remained stable and 4 patients progressed in CKD stage. Patients who experienced a decrease in CKD stage (regression) had significantly higher S-ETP levels patients regressed, 11 patients remained stable and 4 patients progressed in CKD stage. Patients who experienced a decrease in CKD stage (regression) had significantly higher S-ETP levels patients regressed, 11 patients remained stable and 4 patients progressed.

DISCUSSION

Reliable biomarkers for non-invasive assessment of kidney fibrosis burden and progression in patients with kidney diseases are lacking. The ECM holds great promise as a source of new markers for the detection of early alterations leading to disease progression [34]. The main finding of this work is that the matrikine ETP, measured by the PRO-C6 assay, correlated with burden of fibrosis in the kidneys of IgAN patients and AAV.

Table 3. ROC curve analysis to determine discriminatory power of biomarkers for advanced fibrosis

| Cohort                | Biomarker | AUC   | 95% CI      | P-value | Sensitivity | Specificity | Criterion |
|-----------------------|-----------|-------|-------------|---------|-------------|-------------|-----------|
| IgAN and AAV discovery| sCr       | 0.795 | 0.698–0.872 | <0.0001 | 87.5        | 69.3        | >3.0      |
|                       | S-ETP     | 0.799 | 0.702–0.876 | <0.0001 | 87.5        | 73.3        | >26.0     |
|                       | U-ETP/Cr  | 0.759 | 0.653–0.845 | 0.002   | 81.3        | 72.9        | >16.7     |
|                       | S-DKK-3   | 0.605 | 0.496–0.708 | 0.15    | 73.3        | 56.2        | >73.1     |
|                       | U-DKK-3/Cr | 0.755 | 0.642–0.848 | <0.001  | 91.7        | 66.1        | >3.8      |
|                       | sCr       | 0.834 | 0.738–0.906 | 0.0001  | 75.0        | 87.7        | >2.6      |
|                       | S-ETP     | 0.822 | 0.725–0.897 | <0.0001 | 83.3        | 68.5        | >15.4     |
|                       | U-ETP/Cr  | 0.847 | 0.732–0.926 | <0.0001 | 100         | 61.8        | >2.4      |

ROC criteria: Banff score ci3 (advanced interstitial fibrosis) versus ci0–ci2 (low to moderate interstitial fibrosis).
Table 4. Multiple regression analysis to determine the association of biomarkers with the extent of fibrosis (%)

| Cohort               | Model | Method     | $\log_{10}(\text{S-ETP})$ | $\log_{10}(\text{U-ETP/Cr})$ | $\log_{10}(\text{S-DKK-3})$ | $\log_{10}(\text{U-DKK-3/Cr})$ | $\log_{10}(\text{sCr})$ | $\log_{10}(\text{PU})$ |
|----------------------|-------|------------|---------------------------|------------------------------|-----------------------------|------------------------------|------------------------|------------------------|
| IgAN and AAV discovery | 1     | Enter      | 0.47**                   | 0.08                         | 0.02                        | -0.09                       | NR                     | NR                     |
|                      | 2     | Enter      | 0.38*                    | 0.07                         | 0.03                        | -1.00                       | 0.04                   | -1.00                  |
|                      | 3     | Enter      | 0.37*                    | 0.07                         | 0.02                        | -1.00                       | 0.05                   | 0.03                   |
|                      | 4     | Forward    | 0.65***                  | NR                           | NR                          | NR                          | NR                     | NR                     |

Statistical significance.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Method: Enter (enter all variables in the model in one single step), Forward (enter significant variables sequentially).
NR, not retained in the model.

FIGURE 3: ETP levels in the validation cohort according to CKD stages (A), Banff scores (B) and Spearman’s rank correlations with fibrosis levels (C). (A and B) Data are presented on a log$_{10}$ scale as median with IQR and statistical differences were assessed by Kruskal–Wallis test; *P < 0.05, **P < 0.001, ****P < 0.0001. (C) ETP levels are presented on a log$_{10}$ scale.

patients. Based on multiple regression analysis including S-ETP and sCr, only S-ETP and not sCr was independently associated with the degree of fibrosis. Moreover, high baseline S-ETP levels were able to identify AAV patients that regressed in CKD stage within a follow-up period of 3 years. In addition, ETP was superior to the known fibrosis biomarker DKK-3 in reflecting fibrosis burden.

It is well-established that not only are baseline eGFR and PU risk factors of CKD progression, but the degree of glomerulosclerosis, interstitial fibrosis and tubular atrophy are also important predictors of long-term kidney outcome in patients with CKD [35, 36]. As tubulointerstitial fibrosis remains a powerful predictor of future disease progression [13, 14], biomarkers reflecting altered turnover of key components of fibrosis hold great promise as a surrogate to monitoring changes in the tissue. Such changes may reflect the destruction of the renal parenchyma. Seminal studies have shown that collagens are not merely structural entities but can release fragments with paracrine and endocrine properties, termed matrikines [15, 16]. COL VI is expressed at low levels in healthy adult kidneys [18] and is markedly upregulated in patients with renal fibrosis [19, 20]. When COL VI is produced by fibroblasts, ETP, a fragment with important signalling properties, is released from the $\alpha$3 chain [21, 37]. The PRO-C6 assay detects the released fragment, and thus reflects both COL VI formation and levels of ETP. ETP was previously identified as a novel prognostic biomarker of kidney-related outcome in different populations of CKD patients [19, 24, 25]. ETP was highly present in human kidneys with fibrotic foci and inflammatory cell infiltration, in areas co-localizing with markedly increased total COL VI staining. Even though COL VI was present in histologically normal kidneys, no ETP staining was observed [19].

Here, we explored for the first time whether levels of ETP in serum and urine samples taken on the same day of renal biopsy reflect the fibrosis burden in patients with IgAN and in patients with AAV. The increased levels of ETP were related to an increased level of fibrosis in the biopsies, regardless of the used fibrosis score. When investigating which variables best described the extent of histologically confirmed fibrosis, S-ETP was the only variable retained in the final model. By measuring ETP, a molecule that is directly involved in the structural changes that takes place during development of renal fibrosis, earlier diagnosis and detection of disease progression might be possible. This is especially important as surrogate markers of kidney function such as sCr reflect delayed changes due to the concept of ‘renal reserve’; during progressive destruction of nephrons, hyperfiltration and compensatory hypertrophy of the remaining healthy nephrons can maintain a normal GFR even though pathological structural changes are already in place [38, 39]. S-ETP and U-ETP/Cr levels were also able to discriminate between AAV patients whose glomerular injury in biopsies were classified as focal, associated with a good renal outcome, and...
sclerotic, associated with the poorest prognosis (advancement to ESKD and death within 1 year after diagnosis) [33]. ETP levels may in part reflect increased deposition of COL VI in the glomerulus, which is in line with previous studies showing that COL VI replaces COL IV in the glomerular basement membrane in diabetic glomeruli [40].

In alignment with previous findings [26], we showed that U-ETP/Cr correlated to the extent of interstitial fibrosis in the biopsies from IgAN patients. However, ETP appeared to have a superior association to fibrosis burden than did DKK-3. ETP has previously been explored as a marker of lung diseases and high S-ETP levels were associated with an increased risk of mortality in chronic obstructive pulmonary disease [41]. Our data indicate that the elevated ETP levels were not influenced by pulmonary involvement with signs of fibrotic changes. In this study, it was not possible to quantify the degree of lung fibrosis in the AAV patients; therefore, it is not possible to draw conclusions on the relationship of the marker with lung fibrosis, as the nature of pulmonary involvement in these patients may not be related to fibrosis.

During the 3-year follow-up, AAV patients who had an improved kidney function also had a higher baseline level of S-ETP compared with patients with stable or decline in kidney function. Since all AAV patients received treatment after diagnosis, this might indicate that high levels of S-ETP at baseline identified patients with a more active disease, who are more prone to respond to immunosuppressive treatment. This would also be in line with the effects of ETP, which is a matrikine promoting a proinflammatory environment that drives fibrosis [37]. There was no difference between the groups at the 1-year follow-up, either in the IgAN or in the AAV population. However, as a 1-year follow-up time is short, especially for IgAN patients who have a slowly progressing disease, this could be expected.

The association of ETP with the level of fibrosis in the kidney was verified in the validation cohort of patients with IgAN, confirming the robustness of ETP, measured in both serum and urine, as a marker of histologically confirmed fibrosis.

In conclusion, both S-ETP and U-ETP/Cr levels reflect the burden of histologically confirmed fibrosis in the kidneys from patients with IgAN and patients with AAV. The high correlation between S-ETP and U-ETP/Cr indicates that changes in the biomarker levels in serum of patients in this study are not a result of impaired kidney function, but rather a reflection of an actual increased COL VI production, which accurately reflects the fibrosis burden in the kidney. The results presented in this study emphasize the potential of ETP as a non-invasive biomarker of interstitial fibrosis and tubular atrophy that might supplement kidney biopsies and may aid in the evaluation of anti-fibrotic compounds.

**ACKNOWLEDGEMENTS**

The authors would like to thank all patients participating in this study.

**FUNDING**

The authors thank the following for financial support: the Danish Research Foundation (DDF), Ministry of Health, Czech Republic (project RVO-VFN64165) and Ministry of Education, Czech Republic (project PROGRES Q25/LF1).

**AUTHORS’ CONTRIBUTIONS**

V.T., Z.H., F.G. and N.S. designed the study. N.S. performed the statistical analysis, made the figures and drafted the paper. All authors acquired the data, contributed to the interpretation of findings, revision of the paper and approval of the final version of the manuscript.

**CONFLICT OF INTEREST STATEMENT**

F.G., D.G.K.R. and M.A.K. are full-time employees at Nordic Bioscience. N.S. is full-time employee at Nordic Bioscience and the University of Copenhagen. Nordic Bioscience is a privately owned, small- to medium-sized enterprise partly focused on the development of biomarkers. None of the authors received fees, bonuses or other benefits for the work described in this article. F.G. and M.A.K. hold stock in Nordic Bioscience. The patent for the PRO-C6 ELISA used in this work is owned by Nordic Bioscience. The funder provided support in the form of salaries for authors N.S., F.G., D.G.K.R. and M.A.K., but did not have any additional role in

---

**FIGURE 4:** Baseline ETP levels in patients with AAV divided into groups based on changes in CKD stage from baseline to the 3-year follow-up. Serum (A) and urinary (B) ETP levels. Data are presented on a linear (A) and log10 scale (B) as median with IQR and statistical differences were assessed by Kruskal–Wallis test; *P < 0.05.

Endotrophin reflects renal fibrosis

![Graph showing baseline ETP levels in patients with AAV divided into groups based on changes in CKD stage from baseline to the 3-year follow-up.](image-url)
the study design, data collection and analysis, decision to publish or preparation of the manuscript. All other authors report no competing financial interests relevant to this article. The results presented in this article have not been published previously in whole or part, except in abstract format.

DATA AVAILABILITY STATEMENT

The data underlying this article will be shared on reasonable request to the corresponding author.

REFERENCES

1. Penfold RS, Prendergast M, McAdoo S et al. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis 2018; 11: 137–148
2. Maixnerova D, Jancova E, Skibova J et al. Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994–2011. J Nephrol 2014; 28: 39–49
3. Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2017; 33: 763–777
4. Canetta PA, Kiryukh K, Appel GB. Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol 2014; 9: 617–625
5. Coppo R, Davin JC. The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy. Pediatr Nephrol 2015; 30: 189–192
6. Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 2017; 12: 1680–1691
7. Weidner S, Geus S, Hafezi-Rachiti S et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19: 1403–1411
8. Hauer HA, Rajema IM, Hagen EC et al. Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant 2002; 17: 587–596
9. Hruskova Z, Honsova E, Berden AE et al. Repeat protocol renal biopsy in ANCA-associated renal vasculitis. Nephrol Dial Transplant 2014; 29: 1728–1732
10. Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006; 70: 1694–1705
11. Haubitz M, Good DM, Woywodt A et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009; 8: 2296–2307
12. Tesar V, Hruskova Z, Avacopan in the treatment of ANCA-associated vasculitis. Expert Opin Investig Drugs 2018; 27: 491–496
13. Risdon RA, Sloper JC, De Wardener HE. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 2: 363–366
14. Schainuck LI, Striker GE, Cutler RE et al. Structural-functional correlations in renal disease. II: the correlations. Hum Pathol 1970; 1: 631–641
15. Maquart FX, Pasco S, Ramont L et al. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity - Implication in renal disease. II: the correlations. Hum Pathol 1970; 1: 631–641
16. Karsdal MA, Manon-Jensen T, Genoves F et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2015; 308: G807–G830
17. Cescon M, Gattazzo F, Chen P et al. Collagen VI at a glance. J Cell Sci 2015; 128: 3525–3531
18. Magro G, Grasso S, Colombatti A et al. Immunohistochemical distribution of type VI collagen in developing human kidney. Histochem J 1996; 28: 385–390
19. Rasmussen DGK, Fenton A, Jesky M et al. Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Sci Rep 2017; 7: 17328
20. Grom A. Demonstration of collagen type VI and alpha-smooth muscle actin in renal fibrotic injury in man. Nephrol Dial Transplant 1998; 13: 305–312
21. Aigner T, Hambach L, So S et al. The C5 domain of Col6A3 is cleaved off from the Col6 fibrils immediately after secretion. Biochem Biophys Res Commun 2002; 748: 743–748
22. Heumüller SE, Talantikte M, Napolí M et al. C-terminal proteolysis of the collagen VI α3 chain by BMP-1 and proprotein convertase(s) releases endotrophin in fragments of different sizes. J Biol Chem 2009; 284: 13769–13780
23. Sun K, Park J, Gupta OT et al. Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction. Nat Commun 2014; 5: 3485
24. Fenton A, Jesky MD, Ferro C et al. Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. PLoS One 2017; 12: e0173200
25. Rasmussen DGK, Hansen TW, von Scholten BJ et al. Higher collagen VI formation is associated with all-cause mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2018; 41: 1493–1500
26. Federico G, Meister M, Mathow D et al. Tubular dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight 2016; 1: e84916
27. Zewinger S, Rauan T, Rudnicky M et al. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 2018; 29: 2722–2733
28. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604
29. Trimarchi H, Barratt J, Cattran DC et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 2017; 91: 1014–1021
30. Loupy A, Haas M, Solez K et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant 2017; 17: 28–41
31. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628–1636
32. Sun S, Henriksen K, Karsdal MA et al. Collagen type III and VI turnover in response to long-term immobilization. PLoS One 2015; 10: e0144525
33. Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J 2015; 8: 343–350
34. Genoves F, Manresa AA, Leeming DJ et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis. Fibrogen Tissue Repair 2014; 7: 1–14
35. Wang H, Zheng C, Lu Y et al. Urinary fibronectin as a predictor of progression of CKD. Clin J Am Soc Nephrol 2012; 7: 1922–1929
36. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24: 179–196
37. Park J, Scherer PE. Adipocyte-derived endotrophin promotes malignant tumor progression. J Clin Invest 2012; 122: 4243–4256
38. Devarajan P. The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 2010; 17: 469–479
39. Sandilands EA, Dhaun N, Dear JW et al. Measurement of renal function in patients with chronic kidney disease. Br J Clin Pharmacol 2013; 76: 504–515
40. Nellis AG, Schleicher ED, Wiest I et al. Immunohistochemical localization of collagen VI in diabetic glomeruli. Kidney Int 1994; 45: 1648–1656
41. Stolz D, Leeming DJ, Kristensen JHE et al. Systemic biomarkers of collagen and elastin turnover are associated with clinically relevant outcomes in COPD. Chest 2017; 151: 47–59

Received: 22.12.2020; Editorial decision: 31.3.2021